Taiho Pharmaceutical Co
Taiho Pharmaceutical Co., Ltd., commonly referred to as Taiho, is a prominent player in the pharmaceutical industry, headquartered in Japan. Established in 1963, the company has made significant strides in oncology, urology, and other therapeutic areas, positioning itself as a leader in innovative drug development. With a strong operational presence in Japan and expanding markets across Asia and the United States, Taiho is renowned for its commitment to research and development. The company’s core products, including anti-cancer agents and supportive care medications, are distinguished by their efficacy and safety profiles. Taiho's dedication to advancing healthcare has earned it notable achievements, including partnerships with global pharmaceutical firms and recognition for its contributions to cancer treatment. As it continues to grow, Taiho remains focused on delivering high-quality healthcare solutions that meet the evolving needs of patients worldwide.
DitchCarbon Score
How does Taiho Pharmaceutical Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Taiho Pharmaceutical Co's score of 32 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Taiho Pharmaceutical Co's reported carbon emissions
Taiho Pharmaceutical Co., headquartered in Japan, has set ambitious climate commitments aimed at reducing its greenhouse gas (GHG) emissions. Although specific emissions data for the most recent year is not available, the company has established clear reduction targets. Taiho Pharmaceutical is committed to reducing its absolute Scope 1 and Scope 2 GHG emissions by 30% by 2030, using 2017 as the base year. Additionally, the company aims to achieve a 20% reduction in absolute Scope 3 emissions by the same year. These targets align with industry standards for climate action, reflecting a commitment to limit global warming to 2°C. Taiho Pharmaceutical's proactive approach demonstrates its dedication to sustainability within the pharmaceutical sector, contributing to broader efforts to mitigate climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Taiho Pharmaceutical Co is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
